AIMD.P AIM4 Ventures

Annovis Bio to Present at the 2020 BIO Investor Forum

Annovis Bio to Present at the 2020 BIO Investor Forum
EN
12/10/2020

Underlying

AIMD.PAIM4 Ventures

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM4 Ventures

Jonathan Moreland
  • Jonathan Moreland
Free Trial
VALE.N VALE S.A. ADS
LULU Lululemon Athle... ... (+16)

InsiderInsights.com Daily Ratings Report: April 3, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

VALE.N VALE S.A. ADS
LULU LULULEMON ATHLETICA INC
NMM NAVIOS MARITIME PARTNERS
RPAY REPAY HOLDINGS (A)
AIMD.P AIM4 VENTURES
RBLX ROBLOX
QS QUANTUMSCAPE
ZI ZOOMINFO TECHNOLOGIES INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
NRXS NEURAXIS INC
MXF THE MEXICO FUND
GF INC.
NFJ THE NEW GERMANY FUND
INC.
NFJ DIVIDEND
INTEREST & PREMIUM STRATEGY FUND
19h / 10m 19h / 10m 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treat...

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through ...

April 2, 2026 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Publishes Historical Review of Buntanetap in The Scientist

Annovis Publishes Historical Review of Buntanetap in The Scientist MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of an article in The Scientist titled “”, examining the history of discovery and development of buntanetap, the Company's lead drug candidate. As Annovis advances its clinical pipeline wi...

March 31, 2026 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financ...

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced business updates and reported financial results for the fiscal year 2025. In 2025, Annovis achieved a significant milestone in its clinical development program with the initiation of a p...

March 16, 2026 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces Two Presentations at the AD/PD™ 2026 International C...

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (), taking place March 17-21, 2026, in Copenhagen, Denmark. The presentations will highlight cl...

March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch